Galectin Therapeutics Inc.
Galectin Therapeutics Inc. (GALT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
galt · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$11.00
Consensus
$11.00
+359.3% upside
Low
$11.00
Median: $11 · Last Close: $2.40
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.38 | ↓ 0.48% |
1-day model range: $2.36–$2.4. Peak: $2.4 (-0.48%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GALT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-12-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-02 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-12-27 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-11-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-05-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Galectin Therapeutics Inc. (GALT) stock. Of the recent 33 rating actions, 2 were upgrades and 6 were downgrades. 11 analysts currently cover GALT.
Analyst Recommendation Trends
GALT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$36M
↓ 90.6% YoY
Revenue Next Year
$180M
↑ 394.7% YoY
EPS This Year
$-0.49
EPS Next Year
$-0.37
↓ 24.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast GALT EPS of $-0.49 for the current fiscal year, based on estimates from 1 analysts. The GALT revenue forecast is $36M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GALT stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GALT price target is $11.00 (+359.3% upside), with an analyst consensus of Buy.
The GALT short-term stock prediction for tomorrow is $2.38 (-0.48%).
Galectin Therapeutics Inc. trades on NASDAQ under the ticker GALT. The GALT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 82% of covering analysts.
Frequently asked questions
GALT forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month GALT price target is $11.00, with a high forecast of $11.00 and a low of $11.00. The median price target is shown in the chart above when available. This implies +359.3% potential upside from the current price of $2.40.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.